<DOC>
	<DOC>NCT01229332</DOC>
	<brief_summary>A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be explored in subjects with PD and motor fluctuations.</brief_summary>
	<brief_title>A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1. Men and women with idiopathic Parkinson's disease 2. Subjects must experience motor fluctuations associated with LD/CD dosing 3. Modified Hoehn and Yahr stage &lt; 5 4. Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor therapy 5. Women must be postmenopausal, surgically sterilized, or using adequate birth control. Women of childbearing potential must have a negative pregnancy test (serum betaHCG) at screening. 6. Subjects must be age 30 or older. 7. Subjects must be willing and able to give informed consent. 1. Subjects with a clinically significant or unstable medical or surgical condition 2. Subjects with clinically significant psychiatric illness. 3. Premenopausal women, not using birth control method. 4. Subjects who have taken experimental medications within 60 days prior to baseline. 5. Subject who have undergone a neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, transplantation and deep brain stimulation).</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Motor fluctuations levodopa pharmacokinetics carbidopa solution continuous</keyword>
</DOC>